Adverse Effect in Patients with Psoriasis Treated with Interleukin 17A Inhibitor- Secukinumab
Authors
Ardea Milidrag
University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia
Medo Gutić
University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia
Ivana Rodić
Ministry of Health of the Republic of Serbia, Inspection Sector
Ana Pjevač
Syenos Health, Medical and Scientific management
Tatjana Mladenović
Community Health centre Novi Beograd
Vesna Miličić
University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia
Ana Ravić-Nikolić
University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia
DOI: https://doi.org/10.2478/sjecr-2022-0013 | Journal eISSN: 2956-2090 (formerly 2335-075X, 2956-0454) | Journal ISSN: 2956-0454 (formerly 1820-8665)
Language: English
Submitted on: Aug 24, 2021
Accepted on: Mar 26, 2022
Published on: May 27, 2022
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2022 Ardea Milidrag, Medo Gutić, Ivana Rodić, Ana Pjevač, Tatjana Mladenović, Vesna Miličić, Ana Ravić-Nikolić, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.